In the study a significant improvement in pain intensity was observed within 10 minutes and at all subsequent time points measured throughout the assessment period. Adverse events were typical for opioids.
“The results of this study suggest that Fentora may have application beyond its current indication in cancer and provide important support to our strategy for future label expansion in breakthrough pain associated with multiple chronic pain conditions,” said Dr Lesley Russell, senior vice president, Worldwide Medical and Regulatory Operations at Cephalon.
An estimated 51% of people with chronic pain report back pain, making it the most common chronic pain condition, according to the American Chronic Pain Association.
Fentora has been approved by the FDA for patients with cancer pain who can also tolerate opioids.